The pathophysiology and management of thrombotic thrombocytopenic purpura.
Ruggenenti
P
P
Mario Negri Institute for Pharmacological Research, Ospedali Riuniti di Bergamo, Italy.
Remuzzi
G
G
D000293:Adolescent; D000328:Adult; D000367:Age Factors; D001803:Blood Transfusion; D002648:Child; D004730:Endothelium, Vascular / Q000293:injuries / Q000473:pathology; D005260:Female; D006463:Hemolytic-Uremic Syndrome / Q000503:physiopathology; D006801:Humans; D007165:Immunosuppression Therapy; D008297:Male; D008833:Microcirculation; D008875:Middle Aged; D009369:Neoplasms / Q000150:complications; D018384:Oxidative Stress; D010949:Plasma; D010951:Plasma Exchange; D010974:Platelet Aggregation; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D011247:Pregnancy; D011250:Pregnancy Complications, Hematologic / Q000503:physiopathology / Q000628:therapy; D011697:Purpura, Thrombotic Thrombocytopenic / Q000209:etiology / Q000503:physiopathology* / Q000628:therapy; D013156:Splenectomy; D015996:Survival Rate; D014841:von Willebrand Factor / Q000378:metabolism
D010975:Platelet Aggregation Inhibitors; D014841:von Willebrand Factor